Joseph P. Hagan
2017 - Regulus Therapeutics
In 2017, Joseph P. Hagan earned a total compensation of $1.9M as President & Chief Executive Officer at Regulus Therapeutics, a 51% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $175,000 |
|---|---|
| Option Awards | $1,268,367 |
| Salary | $475,300 |
| Other | $3,827 |
| Total | $1,922,494 |
Hagan received $1.3M in option awards, accounting for 66% of the total pay in 2017.
Hagan also received $175K in non-equity incentive plan, $475.3K in salary and $3.8K in other compensation.
Rankings
In 2017, Joseph P. Hagan's compensation ranked 5,696th out of 14,666 executives tracked by ExecPay. In other words, Hagan earned more than 61.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,696 out of 14,666 | 61st |
Division Manufacturing | 2,068 out of 5,772 | 64th |
Major group Chemicals And Allied Products | 640 out of 2,075 | 69th |
Industry group Drugs | 493 out of 1,731 | 72nd |
Industry Pharmaceutical Preparations | 388 out of 1,333 | 71st |
Source: SEC filing on April 20, 2018.
Hagan's colleagues
We found four more compensation records of executives who worked with Joseph P. Hagan at Regulus Therapeutics in 2017.
News
Regulus Therapeutics CEO Joseph Hagan's 2021 pay falls 22% to $1.8M
April 27, 2022
Regulus Therapeutics CEO Joseph Hagan's 2020 pay rises 16% to $2.3M
April 30, 2021
Regulus Therapeutics CEO Joseph Hagan's 2019 pay slips 14% to $2M
April 29, 2020
Regulus Therapeutics CEO Joseph Hagan's 2018 pay jumps 22% to $2.3M
July 1, 2019